about
BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrenceGene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid TumoursMolecular differential diagnosis of follicular thyroid carcinoma and adenoma based on gene expression profiling by using formalin-fixed paraffin-embedded tissues.Molecular signature of cell cycle exit induced in human T lymphoblasts by IL-2 withdrawalAnterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells.The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy.A gene expression signature distinguishes normal tissues of sporadic and radiation-induced papillary thyroid carcinomas.A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrappingGene signature of the post-Chernobyl papillary thyroid cancerDifferences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations.Gene expression profiles for radiation-induced thyroid cancer.Identification of interleukin-1 and interleukin-6-responsive genes in human monocyte-derived macrophages using microarrays.NBL1 and anillin (ANLN) genes over-expression in pancreatic carcinoma.Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer.Metal-proteinase ADAM12, kinesin 14 and checkpoint suppressor 1 as new molecular markers of laryngeal carcinoma.Occurrence of phaeochromocytoma tumours in RET mutation carriers - a single-centre study.Hepatocytes response to interferon alpha levels recorded after liver resection.Guidelines of Polish National Societies Diagnostics and Treatment of Thyroid Carcinoma. 2018 Update.Somatic mutation profiling of follicular thyroid cancer by next generation sequencing.[131-I MIBG therapy of malignant pheochromocytoma and paraganglioma tumors - a single center study.]Coexistence of Promoter Mutations and the V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish PatientsTranscriptomic population markers for human population discriminationExpression pattern of genes in peripheral blood mononuclear cells in diabetic nephropathyGene expression profile of papillary thyroid cancer: sources of variability and diagnostic implicationsUnsupervised analysis of follicular thyroid tumours transcriptome by oligonucleotide microarray gene expression profilingDiscrimination of papillary thyroid cancer from non-cancerous thyroid tissue based on lipid profiling by mass spectrometry imagingCurrent surgical management in RET mutation carriers [Aktualne postępowanie chirurgiczne u nosicieli mutacji proto-onkogenu RET].Novel TG-FGFR1 and TRIM33-NTRK1 transcript fusions in papillary thyroid carcinomaTERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma
P50
Q28075975-96B2F08C-1882-4022-82D9-160B46971ED5Q30313129-C893DE7C-FFF1-4341-8B6E-A1FE09359176Q31141133-AACC7327-C223-4066-9B4A-AF67453D12FEQ33463820-061F0331-DFB2-4F8D-A2B7-20D05486D86AQ33890655-656BB589-678F-495C-B8A2-3CBD48CFDB1EQ35692478-85FCE158-5AE8-40C5-B7BC-F8656469549FQ36239261-E5123E39-0769-4AC4-9A1B-7C8566B66906Q36299076-7546F01C-29FD-46DE-837A-D6EF9BB06241Q36410621-E8DE2CFC-234F-492A-958F-8BF8B90508E2Q36908328-230C0AA4-6003-4CF1-81B4-2CF1BD044108Q37633558-7D002D3D-9E06-4FD9-9B9B-77E2CABE05C8Q37853718-3D167CE7-B8F8-463C-BDD9-D4C952BA8162Q38290702-1D7694D0-44B0-47D9-8569-E1F7D89254A2Q38348214-63726307-4228-48A0-A339-BEC3274A7393Q38815778-AB9EAC23-D6E4-4BD5-9656-2D7E710FDB62Q39962447-8487B6D8-E824-4A1E-A97F-5D5E6B152B3AQ40906427-BBAFE2C9-8444-4D28-8804-22E88B3B8E8AQ46806419-421FF27C-5F52-4F78-B5A3-5DCE45DAFD15Q50016120-9B4BBFD7-50D7-4774-B5B6-9B6FC6ED9803Q51710746-20A8A01A-D92D-4E20-BC84-A39D988850CBQ52592353-66DFD608-687D-4ECD-8895-B121D79A6E01Q57210092-0D6A3B0F-E962-44A8-8F82-108377FF392DQ58797706-95D002DD-067C-48B3-A107-9A3B994933A0Q79690380-86C9BDF9-C405-49E7-B9FF-86A925A259D3Q81448413-9E2A5974-912D-4D98-992C-491C3944109EQ86639257-77F86EB0-DA37-48AC-BFAD-A2C4D0F2484EQ87917371-33E1047B-2E79-4702-908E-CF97D2F11CC3Q91013747-90B36DB9-DC8D-4A6F-A93F-4C33260A7E99Q91143307-042D0B3A-9A59-401F-8AA3-82D95DB9B933Q96604306-FED52926-3F7F-438B-A052-9FBB364FF8B2
P50
description
Pools onderzoekster
@nl
polska biolog, (biologia medyczna)
@pl
researcher ORCID ID = 0000-0002-8989-0075
@en
name
Malgorzata Oczko-Wojciechowska
@ast
Malgorzata Oczko-Wojciechowska
@en
Malgorzata Oczko-Wojciechowska
@es
Malgorzata Oczko-Wojciechowska
@nl
Małgorzata Oczko-Wojciechowska
@ca
Małgorzata Oczko-Wojciechowska
@cs
Małgorzata Oczko-Wojciechowska
@gl
Małgorzata Oczko-Wojciechowska
@hr
Małgorzata Oczko-Wojciechowska
@hsb
Małgorzata Oczko-Wojciechowska
@it
type
label
Malgorzata Oczko-Wojciechowska
@ast
Malgorzata Oczko-Wojciechowska
@en
Malgorzata Oczko-Wojciechowska
@es
Malgorzata Oczko-Wojciechowska
@nl
Małgorzata Oczko-Wojciechowska
@ca
Małgorzata Oczko-Wojciechowska
@cs
Małgorzata Oczko-Wojciechowska
@gl
Małgorzata Oczko-Wojciechowska
@hr
Małgorzata Oczko-Wojciechowska
@hsb
Małgorzata Oczko-Wojciechowska
@it
altLabel
M Oczko-Wojciechowska
@en
Małgorzata Oczko-Wojciechowska
@en
Małgorzata Wioletta Oczko-Wojciechowska
@pl
prefLabel
Malgorzata Oczko-Wojciechowska
@ast
Malgorzata Oczko-Wojciechowska
@en
Malgorzata Oczko-Wojciechowska
@es
Malgorzata Oczko-Wojciechowska
@nl
Małgorzata Oczko-Wojciechowska
@ca
Małgorzata Oczko-Wojciechowska
@cs
Małgorzata Oczko-Wojciechowska
@gl
Małgorzata Oczko-Wojciechowska
@hr
Małgorzata Oczko-Wojciechowska
@hsb
Małgorzata Oczko-Wojciechowska
@it
P214
P1053
P-2272-2018
P106
P1412
P1559
Małgorzata Oczko-Wojciechowska
@pl
P21
P214
P27
P31
P3124
P496
0000-0002-8989-0075
P7859
viaf-315220743